Protein Engineering vol. 16 no. 9 pp. 691-697, 2003
© 2003 Oxford University Press
Inhibition of the CD28–CD80 co-stimulation signal by a CD28-binding affibody ligand developed by combinatorial protein engineering
1Department of Biotechnology, Royal Institute of Technology, AlbaNova University Center, SE-106 90 Stockholm and 2Active Biotech AB, SE-220 07 Lund, Sweden
3 To whom correspondence should be addressed. e-mail: perake{at}biotech.kth.se
CD28 is one of the key molecules for co-stimulatory signalling in T cells. Here, novel ligands (affibodies) showing selective binding to human CD28 (hCD28) have been selected by phage display technology from a protein library constructed through combinatorial mutagenesis of a 58-residue three-helix bundle domain derived from staphylococcal protein A. Analysis of selected affibodies showed a marked sequence homology and biosensor analyses showed that all investigated affibodies bound to hCD28 with micromolar affinities (KD). No cross-reactivity towards the related protein human CTLA-4 could be observed. This lack of cross-reactivity to hCTLA-4 suggests that the recognition site on hCD28 for the affibodies resides outside the conserved MYPPPYY motif. The apparent binding affinity for hCD28 could be improved through fusion to an Fc fragment fusion partner, resulting in a divalent presentation of the affibody ligand. For the majority of selected anti-CD28 affibodies, in co-culture experiments involving Jurkat T-cells and CHO cell lines transfected to express human CD80 (hCD80) or LFA-3 (hLFA-3) on the cell surface, respectively, pre-incubation of Jurkat cells with affibodies resulted in inhibition of IL-2 production when they were co-cultured with CHO (hCD80+) cells, but not with CHO (hLFA-3+) cells. For one affibody variant denoted ZCD28:5 a clear concentration-dependent inhibition was seen, indicating that this affibody binds hCD28 and specifically interferes in the interaction between hCD28 and hCD80.
Received March 11, 2003; revised June 30, 2003; accepted July 30, 2003.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. Xu, H. Yee, C. Chan, A. K. Kashyap, L. Horowitz, M. Horowitz, R. R. Bhatt, and R. A. Lerner Combinatorial surrobody libraries PNAS, August 5, 2008; 105(31): 10756 - 10761. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Friedman, E. Nordberg, I. Hoiden-Guthenberg, H. Brismar, G.P. Adams, F.Y. Nilsson, J. Carlsson, and S. Stahl Phage display selection of Affibody molecules with specific binding to the extracellular domain of the epidermal growth factor receptor Protein Eng. Des. Sel., April 23, 2007; (2007) gzm011v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Kolly, M. A. Thiel, T. Herrmann, and A. Pluckthun Monovalent antibody scFv fragments selected to modulate T-cell activation by inhibition of CD86-CD28 interaction Protein Eng. Des. Sel., February 8, 2007; (2007) gzl058v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Orlova, M. Magnusson, T. L.J. Eriksson, M. Nilsson, B. Larsson, I. Hoiden-Guthenberg, C. Widstrom, J. Carlsson, V. Tolmachev, S. Stahl, et al. Tumor Imaging Using a Picomolar Affinity HER2 Binding Affibody Molecule. Cancer Res., April 15, 2006; 66(8): 4339 - 4348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Wikman, A.-C. Steffen, E. Gunneriusson, V. Tolmachev, G.P. Adams, J. Carlsson, and S. Stahl Selection and characterization of HER2/neu-binding affibody ligands Protein Eng. Des. Sel., May 1, 2004; 17(5): 455 - 462. [Abstract] [Full Text] [PDF]
|
|